Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis

BACKGROUND: COVID-19 threatens to quickly overwhelm our existing critical care infrastructure in the USA. Systemic tissue plasminogen activator (tPA) has been previously demonstrated to improve PaO(2)/FiO(2) (mmHg) when given to critically ill patients with acute respiratory distress syndrome (ARDS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudhury, Rashikh, Barrett, Christopher D., Moore, Hunter B., Moore, Ernest E., McIntyre, Robert C., Moore, Peter K., Talmor, Daniel S., Nydam, Trevor L., Yaffe, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169373/
https://www.ncbi.nlm.nih.gov/pubmed/32312290
http://dx.doi.org/10.1186/s13017-020-00305-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169373/
https://www.ncbi.nlm.nih.gov/pubmed/32312290
http://dx.doi.org/10.1186/s13017-020-00305-4

Ejemplares similares